{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'The minimum titer for samples positive in the ADA assay is based on the minimum required', 'dilution of the assay. It will be classified as', 'Low (Titer <1000)', 'Moderate (1000<Titer 10 000)', 'High (Titer >>10000)', '11.4.4.3 Pharmacodynamics and Phenotyping', 'The values to be used as baselines will be those collected at Visit 2 (Day 1). If any of the', 'scheduled assessments on Day 1 are technically disqualified (eg, insufficient sample), then values', 'determined in any other samples collected prior to the first IMP administration can be used as', 'baseline.', 'For all parameters, raw data, absolute changes from baseline and percent changes from baseline', 'will be summarized in descriptive statistics by treatment group and time point.', 'Summary plots (mean SEM) on raw data, absolute changes from baseline and percent changes', 'from baseline will be provided by treatment group.', 'As part of exploratory analysis, correlations between the baseline values for biomarkers and', 'efficacy endpoints will be assessed.', '11.4.5 Analyses of Patient Reported Outcomes (Health-related Quality of Life/Health', 'Economics Variables)', 'Patient reported outcome variables collected in this study include the ACQ-IA questionnaire', 'ACQ-7 score, PAQLQ(S)-IA score, PACQLQ score, and PRQLQ-IA score (in those with history', 'of allergic rhinitis). The change from baseline for these endpoints will be analyzed using MMRM', 'in the same fashion as for the endpoint of pre-bronchodilator % predicted FEV1. The covariates to', 'be included are treatment, age, weight (30kg, >30kg), region, baseline eosinophil level', '(<300 cells/L, >300 cells/L), baseline FeNO level (<20 ppb, >20 ppb), baseline ICS dose level', '(medium/high), visit, treatment-by-visit interaction, corresponding baseline value and baseline-', 'by-visit interaction. Descriptive statistics including number of patients, mean, standard error and', 'LS means will be provided for each timepoint. In addition, differences in LS means, the', 'corresponding 95% CI and the p-value will be derived from the MMRM model for comparison of', 'dupilumab against placebo at each timepoint. Note that PRQLQ-IA score (in those with history of', 'allergic rhinitis) will only be analyzed for patients with the history of allergic rhinitis.', '11.5 INTERIM ANALYSIS', 'There is no interim analysis planned for this study.', 'Property of the Sanofi Group - strictly confidential', 'Page 121', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '11.6 PLANNED DATABASE LOCK', 'The database lock is planned based on the time when all randomized patients reach complete', 'week 52 visit or discontinue from the study before week 52. Analyses will be based on all data', 'collected up to this database lock and will be considered as the final analyses in the CSR (Clinical', 'Study Report). Additional data between database lock and last patient completing last visit will be', 'summarized in a CSR addendum', 'Property of the Sanofi Group - strictly confidential', 'Page 122', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '12', 'ETHICAL AND REGULATORY CONSIDERATIONS', '12.1 ETHICAL AND REGULATORY STANDARDS', 'This clinical trial will be conducted by the Sponsor, the Investigator, and delegated Investigator', 'staff and Sub-investigator, in accordance with consensus ethics principles derived from', 'international ethics guidelines, including the Declaration of Helsinki, and the International', 'Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for', 'Human Use (ICH) guidelines for good clinical practice (GCP), all applicable laws, rules and', 'regulations.', 'This clinical trial will be recorded in a free, publicly accessible, internet-based registry, no later', 'than 21 days after the first patient enrollment, in compliance with applicable regulatory', 'requirements and with Sanofi public disclosure commitments.', '12.2 INFORMED CONSENT', 'The Investigator (according to applicable regulatory requirements), or a person designated by the', \"Investigator, and under the Investigator's responsibility, should fully inform the patient who is\", '>6 years and his/her parent(s)/caregiver(s)/legal guardian(s) of all pertinent aspects of the clinical', 'trial including the written information giving approval/favorable opinion by the Ethics Committee', '(IRB/IEC). All patients/parent(s)/caregiver(s)/legal guardian(s) should be informed to the fullest', 'extent possible about the study, in their language and in terms they are able to understand.', 'It is the responsibility of the Investigator or designee (if acceptable by local regulations) to obtain', 'written informed assent (IA) from each patient >6 years of age (or above an age determined by the', 'IRB/IEC and in according with the local regulations and requirements), and written ICF from', \"each patient's parent(s)/caregiver(s)/legal guardian(s) prior to the patient's participation in the\", 'study, and prior to initiating any screening procedures. The written IAF/ICF should be signed and', 'dated by the patient(s) and parent(s)/caregiver(s)/legal guardian(s) respectively.', 'Local law must be observed in deciding whether 1 or both parents/guardians consent is required.', 'If only 1 parent or guardian signs the consent form, the Investigator must document the reason the', 'other parent or guardian did not sign. The patient may also be required to sign and date the ICF as', 'determined by the IRB/IEC and in accordance with the local regulations and requirements.', 'Patient(s)/parent(s)/caregiver(s)/legal guardian(s) who can write but cannot read will have', 'the assent/consent form read to them before writing their name on the form', 'Patient(s)/parent(s)/caregiver(s)/lega guardian(s) who can understand but who can either', 'write nor read will have the informed assent/consent form read to them in presence of an', 'impartial witness, who will sign and date the assent/consent form to confirm that informed', 'consent was given.', 'The original of each completed informed assent/consent form (IAF/ICF) must be retained by the', \"Investigator as part of the patient's study record and a copy of the signed assent/consent form\", \"must be given to the patient/patient's parent(s)/caregiver(s)/legal guardian(s)\", 'Property of the Sanofi Group - strictly confidential', 'Page 123', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}